Wnt signaling in cancer pathogenesis and therapeutics

Naoko Takebe, Lawrence Lum, S. Percy Ivy

Research output: Chapter in Book/Report/Conference proceedingChapter

1 Citation (Scopus)

Abstract

This chapter presents a concise review of Wnt signaling in cancer pathogenesis. Our focus is on the description of novel agents in preclinical and/or clinical stage development, which inhibit dysfunctional Wnt signaling. We discuss growing evidence that the Wnt pathway supports cellular proliferation by sustaining renewal of cancer initiating stem cells. We also review ongoing therapeutic efforts to inhibit pathway activity in a broad range of cancers. The rationale for targeting this pathway is well justified, based on the association of colorectal cancer with deregulation of Wnt signaling. Therefore, the Wnt pathway may represent an important target for the development of novel anticancer therapeutics.

Original languageEnglish (US)
Title of host publicationSignaling Pathways in Cancer Pathogenesis and Therapy
PublisherSpringer New York
Pages81-94
Number of pages14
ISBN (Electronic)9781461412168
ISBN (Print)1461412153, 9781461412151
DOIs
StatePublished - Aug 1 2013
Externally publishedYes

Fingerprint

Wnt Signaling Pathway
Neoplastic Stem Cells
Colorectal Neoplasms
Neoplasms
Cell Proliferation
Therapeutics

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Takebe, N., Lum, L., & Ivy, S. P. (2013). Wnt signaling in cancer pathogenesis and therapeutics. In Signaling Pathways in Cancer Pathogenesis and Therapy (pp. 81-94). Springer New York. https://doi.org/10.1007/978-1-4614-1216-8_6

Wnt signaling in cancer pathogenesis and therapeutics. / Takebe, Naoko; Lum, Lawrence; Ivy, S. Percy.

Signaling Pathways in Cancer Pathogenesis and Therapy. Springer New York, 2013. p. 81-94.

Research output: Chapter in Book/Report/Conference proceedingChapter

Takebe, N, Lum, L & Ivy, SP 2013, Wnt signaling in cancer pathogenesis and therapeutics. in Signaling Pathways in Cancer Pathogenesis and Therapy. Springer New York, pp. 81-94. https://doi.org/10.1007/978-1-4614-1216-8_6
Takebe N, Lum L, Ivy SP. Wnt signaling in cancer pathogenesis and therapeutics. In Signaling Pathways in Cancer Pathogenesis and Therapy. Springer New York. 2013. p. 81-94 https://doi.org/10.1007/978-1-4614-1216-8_6
Takebe, Naoko ; Lum, Lawrence ; Ivy, S. Percy. / Wnt signaling in cancer pathogenesis and therapeutics. Signaling Pathways in Cancer Pathogenesis and Therapy. Springer New York, 2013. pp. 81-94
@inbook{3744c3c28ccd4803ac2d4a6c52634f3d,
title = "Wnt signaling in cancer pathogenesis and therapeutics",
abstract = "This chapter presents a concise review of Wnt signaling in cancer pathogenesis. Our focus is on the description of novel agents in preclinical and/or clinical stage development, which inhibit dysfunctional Wnt signaling. We discuss growing evidence that the Wnt pathway supports cellular proliferation by sustaining renewal of cancer initiating stem cells. We also review ongoing therapeutic efforts to inhibit pathway activity in a broad range of cancers. The rationale for targeting this pathway is well justified, based on the association of colorectal cancer with deregulation of Wnt signaling. Therefore, the Wnt pathway may represent an important target for the development of novel anticancer therapeutics.",
author = "Naoko Takebe and Lawrence Lum and Ivy, {S. Percy}",
year = "2013",
month = "8",
day = "1",
doi = "10.1007/978-1-4614-1216-8_6",
language = "English (US)",
isbn = "1461412153",
pages = "81--94",
booktitle = "Signaling Pathways in Cancer Pathogenesis and Therapy",
publisher = "Springer New York",

}

TY - CHAP

T1 - Wnt signaling in cancer pathogenesis and therapeutics

AU - Takebe, Naoko

AU - Lum, Lawrence

AU - Ivy, S. Percy

PY - 2013/8/1

Y1 - 2013/8/1

N2 - This chapter presents a concise review of Wnt signaling in cancer pathogenesis. Our focus is on the description of novel agents in preclinical and/or clinical stage development, which inhibit dysfunctional Wnt signaling. We discuss growing evidence that the Wnt pathway supports cellular proliferation by sustaining renewal of cancer initiating stem cells. We also review ongoing therapeutic efforts to inhibit pathway activity in a broad range of cancers. The rationale for targeting this pathway is well justified, based on the association of colorectal cancer with deregulation of Wnt signaling. Therefore, the Wnt pathway may represent an important target for the development of novel anticancer therapeutics.

AB - This chapter presents a concise review of Wnt signaling in cancer pathogenesis. Our focus is on the description of novel agents in preclinical and/or clinical stage development, which inhibit dysfunctional Wnt signaling. We discuss growing evidence that the Wnt pathway supports cellular proliferation by sustaining renewal of cancer initiating stem cells. We also review ongoing therapeutic efforts to inhibit pathway activity in a broad range of cancers. The rationale for targeting this pathway is well justified, based on the association of colorectal cancer with deregulation of Wnt signaling. Therefore, the Wnt pathway may represent an important target for the development of novel anticancer therapeutics.

UR - http://www.scopus.com/inward/record.url?scp=84929285294&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84929285294&partnerID=8YFLogxK

U2 - 10.1007/978-1-4614-1216-8_6

DO - 10.1007/978-1-4614-1216-8_6

M3 - Chapter

AN - SCOPUS:84929285294

SN - 1461412153

SN - 9781461412151

SP - 81

EP - 94

BT - Signaling Pathways in Cancer Pathogenesis and Therapy

PB - Springer New York

ER -